N/A N=601 Genetic Testing for Type 2 Diabetes
Diabetes Mellitus
Primary: Weight — 103.8; 100.7 kg — p=0.44
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=115,484 Early Detection of GEnetic Risk (EDGE)
Genetic Predisposition
Primary: Rates of Screening — 9892; 3813 Participants — p=0.0074
N/A N=148 Implementation of Genomics in Substance Use Disorder Treatment
Tobacco Use Disorder · Smoking Cessation · Tobacco Use Cessation
Primary: Change in Use of Smoking Cessation Pharmacotherapy in Past 30 Days — 11; 9; 9; 2 Participants
Phase 1 N=25 Developing Clinical Tools to Communicate Genetic Risk for Individuals Who Are Clinical High Risk for Psychosis
Psychosis
Primary: Change From Baseline in Perceived Treatment Efficacy — 2.6; 1.6; 0.5; 0.5 score on a scale
N/A N=798 Communicating Risk Information for Obesity
Obesity
Primary: Intentions to Lose Weight - Effect of Study Arm on Outcomes — 3.06; 3.37; 3.26; 3.26 units on a scale — p=.0150
N/A N=80 Genetic Determinants of the Coronary Microvascular Obstruction in PCI
Myocardial Infarction · No-Reflow Phenomenon
Primary: Hospital Mortality Rate — 6; 2 Participants
N/A N=154 Genetic Determinants of Response to Beta Blockade
Healthy
Primary: Reduction in Heart Rate — 7.9; 6; 3.3; 9.6 beats per minute
N/A N=38 Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation
Atrial Fibrillation
Primary: Change in Pre- and Post-atenolol Ventricular Rate Response After 5 Minutes of Exercise — -10; -13 beats per minute
N/A N=1,223 DISCOVERY: Diagnostic Data and Genetic Polymorphisms in ICD Patients.
Death, Sudden, Cardiac · Ventricular Fibrillation · Tachycardia
Primary: Number of Patients With Ventricular Arrhythmia <400 Msec. by GNAS c.393C>T Genotype — 63; 136; 98 participants with VT < 400 msec
N/A N=200 Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease
Coronary Heart Disease, Susceptibility to, 5 · Prediabetic State
Primary: Dietary Intake as Measured by Percent Energy From Fat — 33.75; 34.9; 33.72; 35.05 percent energy from fat — p=0.1073
Phase 4 N=28 Implementation of PPI Medication PGX Testing
Gastroesophageal Reflux
Primary: Count of Patients Agreeing to Volunteer for the Study — 28 Participants
N/A N=103 Developing Genetic Education for Smoking Cessation
Tobacco Smoking
Primary: Knowledge of Genetic Contributions to Smoking — 5.25; 3.73; 7.04; 4.03 score on a scale — p=<0.01
N/A N=400 The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study
Healthy Volunteers
Primary: Baseline and Peak TNF-alpha Values as Categorized by Race and Gender — 1.08; 43.48; 1.03; 37.28 pg/ml
N/A N=88 Pharmacogenetics of b2-Agonists in Asthma.
Asthma
Primary: Log10 PC20 to Methacholine After Visit 2 — 0.54; 0.48; 0.16; 0.53 log10 mg/mL — p=0.27
Phase 4 N=135 Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment
Major Depression
Primary: Montgomery-Asberg's Depression Rating Scale — 9.2 score on a scale
N/A N=9 Genetic and Neural Factors in Alcohol-Related Cognition
Alcohol Abuse
Primary: Changes in Alcohol-influenced Behavior — 1.56; 1.49 units on a scale
N/A N=166 Risk Communication in African American Smokers
Lung Cancer
Primary: Motivation to Quit Smoking — 4.95; 3.30; 5.49; 4.52 units on a scale
N/A N=11 Familial Hyperlipidemia Family Registry
Familial Hyperlipidemia
Primary: Familial Hypercholesterolemia (FH) Determination for Family Members of School Children With Elevated Cholesterol and Documented FH Variant — 3; 8 participants
N/A N=538 Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes
Schizophrenia
Primary: Genetic Linkage — 5.2 log (odds ratio) — p=<0.001
N/A N=159 Genetically Guided Statin Therapy
Hypercholesterolemia · Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) Reductase Inhibitors Adverse Reaction
Primary: Morisky Medication Adherence Scale (MMAS) Score — 6.8; 6.9; 6.8; 7.1 units on a scale — p=0.96
N/A N=145 The Personalized Nutrition Study
Weight Loss
Primary: Weight Change — -5.5; -4.1; -5.3; -5.1 kg
N/A N=24 Smokers' Response to Nicotine Dependence Genotyping
Cigarette Smoking · Nicotine Dependence
Primary: Change in Baseline Smoking Abstinence at 6 and 10 Weeks After Genotyping Results — 1; 0; 7; 11 Participants
Phase 4 N=682 Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)
Platelet Aggregation Inhibitors · Coronary Heart Disease
Primary: Changes in Platelet Function in Response to Clopidogrel — 38.51; 14.06 percentage of maximum aggregation change
N/A N=360 Alcohol Metabolism and Disease Risk in Asians
Healthy
Primary: Peak Number of Alcohol Drinks Consumed in a Day — 3.7; 4.2; 3.4; 3.0 drinks — p=.81
Phase 4 N=31 Genetics and HIV-1 Protease Inhibitors
HIV
Primary: Day 7 Atazanavir Oral Clearance — .25; .18 L/h/kg
Phase 2 N=50 Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant
Type 2 Diabetes
Primary: Insulin Secretion — 5; 29 % increase of Ins30
N/A N=57 Personalized Nutrition in Young Adults: The Ability of Genetic Information to Motivate Changes in Omega-3 Consumption
Health Behaviour · Nutrition Intervention · Impaired Health
Primary: Omega-3 Dietary Intake — 190.16; 211.50; 395.82; 323.23 mg/day
N/A N=19 Genetic Influences on Response to Gait Rehabilitation in Parkinson's Disease
Parkinson's Disease
Primary: Gait Speed (m/s) — 1.14; 1.21; 1.22; 1.20 m/s
Phase 4 N=1,406 Biomarker and Genetic Predictors of Erenumab Treatment Response
Migraine
Primary: Percentage of Participants Achieving at Least a 50% Reduction From Baseline in Mean MMDs Over Months 4, 5, and 6 in Relation to mPRS — 54.9 percentage of participants…
N/A N=15 Genetic-specific Effects of Fructose on Liver Lipogenesis
NAFLD
Primary: Mean Change in Liver Fat Content Based on Elastography — -0.15; 1.10 kilopascal (kPa) — p=0.40